Brief: European Commission Approves Amgen's Uplizna® For Generalized Myasthenia Gravis
12/02/2026 14:32
Feb 12 (Reuters) - Amgen Inc AMGN.O: EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS Source text: ID:nPreHdJjPa Further company coverage: AMGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsFactbox: Global drugmakers invest billions to boost US presence
China's Harbour BioMed to focus on another patent case after $20 million damages award
Amgen owes $20.2 million in antibody patent lawsuit, US jury says (updated)
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen taps research firm to reassess Tavneos data (updated)